Logo
Home
Company ProfileBoards & StaffsMemberships & PartnersAcademy of JournalismCareersBlog(EN)Contact Us
Our JournalsInstruction for AuthorsBrieflands PoliciesPublish My ResearchJournal Management SystemArticle Processing ChargesOpen Peer ReviewPublishing Services
Publish My Book
  1. Brieflands
  2. journals
  3. IJ Pharmaceutical Research
  4. Articles

  5. Assessment of Different Radioiodine Doses for Post-ablation Therapy of Thyroid Remnants: A Systematic Review
  6. Scopus by Title (Ref)

IJ Pharmaceutical Research

Home
Current IssueAll IssuesIn PressAccepted Manuscripts
SearchInstructions
Journal InformationEditors & BoardsIndexing and Listing SourcesJournal MetricsOpen Peer Review (OPR)Publication Ethics and Malpractice StatementReviewer and AE Registration FormSupportContact Us
APC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. AI leveraging solution for thyroid disease: advances and rationale

- Verma S. , et al.

2. Real-world Data on Intermediate-risk Differentiated Thyroid Cancer Biochemical Response to 3700 or 5550 MBq of [131I]Sodium Iodide

- Machado D.M. , et al.

3. Recombinant Human Thyrotropin Plus Radioactive Iodine among Patients with Thyroid Cancer: A Noninferiority Randomized Clinical Trial

- Tan H. , et al.

4. Radioactive Iodine in Differentiated Carcinoma of Thyroid: An Overview

- Singh N.K. , et al.

5. Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect

- Li X. , et al.

HomeSearchInstructionsAPC

Archives

  • Current Issue
  • All Issues
  • In Press
  • Accepted Manuscripts

About Journal

  • Journal Information
  • Editors & Boards
  • Indexing and Listing Sources
  • Journal Metrics
  • Open Peer Review (OPR)
  • Publication Ethics and Malpractice Statement
  • Reviewer and AE Registration Form
  • Support
  • Contact Us
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.